1. Home
  2. GROW vs LIXT Comparison

GROW vs LIXT Comparison

Compare GROW & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U.S. Global Investors Inc.

GROW

U.S. Global Investors Inc.

HOLD

Current Price

$2.62

Market Cap

32.0M

Sector

Finance

ML Signal

HOLD

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$5.20

Market Cap

26.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GROW
LIXT
Founded
1968
2005
Country
United States
United States
Employees
24
3
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.0M
26.5M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
GROW
LIXT
Price
$2.62
$5.20
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
18.0K
55.6K
Earning Date
05-11-2026
05-08-2026
Dividend Yield
3.53%
N/A
EPS Growth
N/A
N/A
EPS
0.27
N/A
Revenue
$23,850,609.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.16
$0.64
52 Week High
$3.65
$6.09

Technical Indicators

Market Signals
Indicator
GROW
LIXT
Relative Strength Index (RSI) 48.64 73.86
Support Level $2.33 $3.69
Resistance Level $2.73 $6.03
Average True Range (ATR) 0.08 0.53
MACD 0.01 0.10
Stochastic Oscillator 43.49 78.60

Price Performance

Historical Comparison
GROW
LIXT

About GROW U.S. Global Investors Inc.

US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: